Lexicon Pharmaceuticals, Inc. (LXRX) Cash Flow Statement
Where LXRX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$67.9M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$67.9M −136.2% margin
- Returned to shareholders
- $572,000
- Change in cash
- −$3.3M cash at year-end $63.3M
Cash from operations
−$67.9M
Investments (net)
+$113.0M
Share buybacks (net)
−$572,000
Net borrowing (repayment)
−$48.0M
Change in cash
−$3.3M
Drawn to scale: where the cash came from and how it was used. Hover for values.
LXRX operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
LXRX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$175.6M2016 | −$67.9M2025 | — | |
| Capital expenditures | $231,0002016 | $02025 | −100.0% | |
| Free cash flow | −$175.9M2016 | −$67.9M2025 | — | |
| Free cash flow margin | −211.0%2016 | −136.2%2025 | +74.8 pts | |
| Stock-based compensation | $7.5M2016 | $12.5M2025 | +5.9%/yr | |
| Dividends paid | $2.0M2016 | $99.9M2023 | +74.6%/yr | |
| Share buybacks (net) | $621,0002016 | $572,0002025 | −0.9%/yr | |
| Capex / revenue | 0.3%2016 | 0.0%2025 | −0.3 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
LXRX cash flow by activity
OperatingInvestingFinancingChange in cash
LXRX net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
LXRX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$50.3M | −$200.4M | −$177.1M | −$101.9M | −$87.8M | −$58.6M | $130.1M | −$120.5M | −$129.1M | −$141.4M |
| Depreciation & amortization | $621,000 | $534,000 | $554,000 | $427,000 | $292,000 | $2.9M | $3.7M | $3.7M | $3.4M | $2.1M |
| Stock-based compensation | $12.5M | $13.5M | $14.3M | $11.5M | $10.6M | $13.3M | $14.2M | $11.7M | $9.5M | $7.5M |
| Change in working capital | −$26.9M | $14.2M | $2.7M | $402,000 | −$10.2M | $31.1M | −$58.3M | −$44.8M | −$59.3M | −$43.5M |
| Other non-cash items | −$3.8M | −$6.6M | −$2.3M | $744,000 | $103,000 | −$131.7M | $24.1M | $1.3M | −$10.0M | −$160,000 |
| Cash from operating activities | −$67.9M | −$178.8M | −$161.9M | −$88.9M | −$87.0M | −$143.0M | $113.8M | −$148.6M | −$185.4M | −$175.6M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$1.0M | −$470,000 | −$1.3M | −$1.2M | −$87,000 | −$70,000 | −$95,000 | −$228,000 | −$231,000 |
| Investments (net) | $113.0M | −$15.4M | −$77.7M | −$69.8M | $3.3M | $209.4M | −$155.8M | $169.7M | $50.8M | $18.5M |
| Acquisitions & other investing | $0 | $1.0M | $28.2M | $0 | $0 | $171.4M | $0 | $0 | $0 | $0 |
| Cash from investing activities | $113.0M | −$15.4M | −$49.9M | −$71.1M | $2.1M | $380.8M | −$155.9M | $169.6M | $50.5M | $18.3M |
| Financing activities | ||||||||||
| Dividends paid | — | — | −$99.9M | — | −$11.7M | −$216.6M | — | — | $0 | −$2.0M |
| Share repurchases & issuance (net) | −$572,000 | −$1.7M | −$824,000 | −$864,000 | −$2.7M | −$1.0M | −$941,000 | −$972,000 | −$1.7M | −$621,000 |
| Net borrowing (repayment) | −$48.0M | $0 | $50.0M | $48.9M | −$11.7M | −$216.6M | −$1.3M | −$2.0M | $143.6M | −$2.0M |
| Shares issued | $0 | $241.3M | $138.8M | $94.2M | $37.1M | $70.0M | $0 | $732,000 | $0 | $0 |
| Other financing | $73,000 | −$1.2M | $100.0M | $0 | $11.7M | $216.6M | $0 | $0 | $8.0M | $5.6M |
| Cash from financing activities | −$48.5M | $238.3M | $188.0M | $142.2M | $22.7M | −$147.6M | −$2.2M | −$2.2M | $149.9M | $987,000 |
| Summary | ||||||||||
| Net change in cash | −$3.3M | $44.2M | −$23.9M | −$17.7M | −$62.2M | $90.2M | −$44.3M | $18.7M | $15.1M | −$156.4M |
| Cash at end of period | $63.3M | $66.7M | $22.5M | $46.3M | $64.1M | $126.3M | $36.1M | $80.4M | $61.7M | $46.6M |
| Free cash flow | −$67.9M | −$179.8M | −$162.4M | −$90.2M | −$88.2M | −$143.1M | $113.7M | −$148.7M | −$185.6M | −$175.9M |
| Free cash flow margin | −136.2% | −578.5% | −13,485.6% | −64,875.5% | −29,610.1% | −596.2% | 35.3% | −235.3% | −205.5% | −211.0% |
| Capex / revenue | 0.0% | 3.3% | 39.0% | 954.0% | 409.7% | 0.4% | 0.0% | 0.2% | 0.3% | 0.3% |
| Operating cash flow / net income | — | — | — | — | — | — | 0.87 | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$32.8M | −$1.0M | −$15.5M | −$12.8M | $3.3M | −$25.3M | −$33.8M | −$64.8M | −$53.4M | −$48.4M | −$49.8M | −$50.5M |
| Depreciation & amortization | $102,000 | $110,000 | $118,000 | $151,000 | $176,000 | $176,000 | $125,000 | $126,000 | $139,000 | $144,000 | $147,000 | $151,000 |
| Stock-based compensation | $6.4M | $3.1M | $2.8M | $3.4M | $3.2M | $3.0M | $1.5M | $2.8M | $4.9M | $4.3M | $3.2M | $3.9M |
| Change in working capital | −$1.9M | −$16.4M | −$4.5M | −$14.3M | $11.2M | −$19.2M | $11.8M | $9.7M | $4.2M | −$11.5M | −$4.3M | $7.9M |
| Other non-cash items | $4.3M | −$462,001 | −$108,000 | −$348,000 | −$833,000 | −$2.5M | −$1.2M | −$1.4M | −$4.4M | $291,000 | $126,000 | −$3.0M |
| Cash from operating activities | −$23.9M | −$14.7M | −$17.2M | −$23.8M | $17.0M | −$43.8M | −$21.5M | −$53.6M | −$48.5M | −$55.1M | −$50.5M | −$41.6M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | −$474,000 | −$307,000 | −$250,000 | $0 | $0 | −$83,000 |
| Investments (net) | −$16.5M | −$70.3M | $4.8M | $52.1M | $15.5M | $40.6M | $53.7M | $53.5M | −$12.3M | −$110.2M | $51.9M | −$39.3M |
| Acquisitions & other investing | −$70.3M | $0 | $0 | $0 | $0 | $0 | $474,000 | $307,000 | $250,000 | $0 | $0 | $83,000 |
| Cash from investing activities | −$86.7M | −$70.3M | $4.8M | $52.1M | $15.5M | $40.6M | $53.7M | $53.5M | −$12.3M | −$110.2M | $51.9M | −$39.3M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | $0 | — | — | −$572,000 | $0 | $0 | $0 | −$1.7M | $211,000 | −$211,000 |
| Net borrowing (repayment) | $739,000 | −$5.0M | −$3.0M | $0 | −$45.0M | $0 | $0 | $0 | — | — | — | — |
| Shares issued | $1.0M | $96.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $241.5M | $0 | $0 |
| Other financing | $86.5M | −$2.8M | $73,000 | $0 | $0 | $0 | −$104,000 | −$916,000 | −$14,000 | −$400,000 | −$212,000 | $1,000 |
| Cash from financing activities | $88.2M | $88.8M | −$2.9M | $0 | −$45.0M | −$572,000 | −$104,000 | −$916,000 | −$14,000 | $239.4M | −$1,000 | −$210,000 |
| Summary | ||||||||||||
| Net change in cash | −$22.4M | $3.8M | −$15.3M | $28.3M | −$12.5M | −$3.8M | $32.1M | −$1.1M | −$60.9M | $74.0M | $1.3M | −$81.2M |
| Cash at end of period | $40.9M | $38.1M | $63.3M | $78.7M | $50.4M | $62.9M | $66.7M | $34.6M | $35.6M | $96.5M | $22.5M | $21.1M |
| Free cash flow | −$23.9M | −$14.7M | −$17.2M | −$23.8M | $17.0M | −$43.8M | −$22.0M | −$53.9M | −$48.8M | −$55.1M | −$50.5M | −$41.7M |
| Free cash flow margin | −3,456.9% | −69.8% | −313.7% | −168.1% | 58.9% | −3,468.9% | −82.7% | −3,081.5% | −2,962.4% | −4,878.8% | −7,200.6% | −25,742.0% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% | 17.5% | 15.2% | 0.0% | 0.0% | 51.2% |
| Operating cash flow / net income | — | — | — | — | 5.23 | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
LXRX cash generation
In fiscal 2025 (ended December 31, 2025), Lexicon Pharmaceuticals generated -$67.9 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$67.9 million, −136.2% of revenue. It returned $0.6 million to shareholders through dividends ($0) and net share buybacks ($0.6 million). Cash and equivalents fell by $3.3 million over the year.
Related: LXRX income statement, LXRX balance sheet. See the LXRX stock overview for the latest quote and news.
LXRX cash flow FAQ
What is Lexicon Pharmaceuticals's free cash flow?
Lexicon Pharmaceuticals's free cash flow was -$67.9 million in fiscal 2025: -$67.9 million of operating cash flow minus $0 of capital expenditures It was -$179.8 million a year earlier..
How much cash does Lexicon Pharmaceuticals generate from operations?
Lexicon Pharmaceuticals generated -$67.9 million of cash from operating activities in fiscal 2025.
How much stock does Lexicon Pharmaceuticals buy back?
Lexicon Pharmaceuticals spent $0.6 million on net share repurchases in fiscal 2025.